Literature DB >> 3943090

Characterization of estrogen and progesterone receptors and the dissociated regulation of growth and progesterone receptor stimulation by estrogen in MDA-MB-134 human breast cancer cells.

G C Reiner, B S Katzenellenbogen.   

Abstract

We have examined the properties of the estrogen receptor and progesterone receptor in MDA-MB-134 human breast cells and have evaluated the effects of estrogen on cell proliferation and progesterone receptor levels in these cells as indices of hormonal sensitivity. These cells contain high levels of estrogen receptor (approximately 1.5 pmol/mg DNA) and low levels of progesterone receptor (0.15 pmol/mg DNA). More than 80% of the estrogen receptor is found in the nuclear fraction in the absence of estrogen, and the Kd of the receptor for estradiol is approximately 1.5 X 10(-10) M. Upon exposure to estradiol, the receptors become occupied, but there is no processing or apparent decrease in either nuclear or total cellular estrogen receptor content, as can be seen in MCF-7 human breast cancer cells. The nuclear estrogen receptor sediments as a 4.6 S species on high salt sucrose gradients, and it can be detected on sodium dodecyl sulfate-polyacrylamide gel immunoblot analysis as a species of molecular weight 65,000, identical to that of the MCF-7 estrogen receptor, using the monoclonal antibodies D75P3 gamma and H222Sp gamma prepared against the MCF-7 estrogen receptor. The estrogen receptor shows binding selectivity for estrogens and antiestrogens, and its affinity for ligands follows the order diethylstilbestrol (190%) greater than estradiol (100%) greater than estriol (13%) greater than tamoxifen (3%), as expected for estrogen receptor. Hence the receptor appears normal in many of its physicochemical properties and in terms of its binding affinity and specificity for estrogens and antiestrogens. Control cells contain low levels of progesterone receptor that display high affinity (Kd = 6 X 10(-9) M) for the synthetic progestin R5020, but exposure to estradiol (10(-11)-10(-7)M) fails to increase cellular progesterone receptor levels. In contrast, estradiol markedly stimulates the rate of cell proliferation, while tamoxifen suppresses the growth of control and of estradiol treated cells. Hence, our data show that these cells, which contain substantial levels of estrogen receptor, respond to estrogen with enhanced cell proliferation but fail to have their progesterone receptor level modulated by estradiol. These cells represent an interesting and unusual situation in which estrogenic regulation of proliferation and the stimulation of progesterone receptor are dissociated. These cells should prove useful in further evaluation of estrogenic regulation of cell proliferation and specific protein synthesis in human breast cancer.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3943090

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  Differential regulation by estrogens of growth and prolactin synthesis in pituitary cells suggests that only a small pool of estrogen receptors is required for growth.

Authors:  T Y Chun; D Gregg; D K Sarkar; J Gorski
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

2.  Immunohistochemical localization of creatine kinase BB in primary breast cancer: correlation with estrogen receptor content.

Authors:  G Scambia; G Santeusanio; P B Panici; S Iacobelli; S Mancuso
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

3.  Immunohistochemical analysis of the topographical relationship between the estrogen- and progesterone receptor in five human breast cancers. A simultaneous demonstration of both nuclear receptors in the same section by using a computer-assisted image processing.

Authors:  H Bonkhoff; N Wernert
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1989

4.  Progestin inhibition of estrogen-dependent proliferation in ZR-75-1 human breast cancer cells: antagonism by insulin.

Authors:  R Poulin; J M Dufour; F Labrie
Journal:  Breast Cancer Res Treat       Date:  1989-07       Impact factor: 4.872

5.  Upmodulation by estrogen of HLA class I expression in breast tumor cell lines.

Authors:  F Rodríguez; F Perán; F Garrido; F Ruiz-Cabello
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

6.  Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.

Authors:  Matthew J Sikora; Kristine L Cooper; Amir Bahreini; Soumya Luthra; Guoying Wang; Uma R Chandran; Nancy E Davidson; David J Dabbs; Alana L Welm; Steffi Oesterreich
Journal:  Cancer Res       Date:  2014-01-14       Impact factor: 12.701

7.  Truncated forms of DNA-binding estrogen receptors in human breast cancer.

Authors:  G K Scott; P Kushner; J L Vigne; C C Benz
Journal:  J Clin Invest       Date:  1991-08       Impact factor: 14.808

8.  ERRgamma mediates tamoxifen resistance in novel models of invasive lobular breast cancer.

Authors:  Rebecca B Riggins; Jennifer P-J Lan; Yuelin Zhu; Uwe Klimach; Alan Zwart; Luciane R Cavalli; Bassem R Haddad; Li Chen; Ting Gong; Jianhua Xuan; Stephen P Ethier; Robert Clarke
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

9.  Differential Regulation and Targeting of Estrogen Receptor α Turnover in Invasive Lobular Breast Carcinoma.

Authors:  Sreeja Sreekumar; Kevin M Levine; Matthew J Sikora; Jian Chen; Nilgun Tasdemir; Dorothy Carter; David J Dabbs; Carolin Meier; Ahmed Basudan; David Boone; Priscilla F McAuliffe; Rachel C Jankowitz; Adrian V Lee; Jennifer M Atkinson; Steffi Oesterreich
Journal:  Endocrinology       Date:  2020-09-01       Impact factor: 4.736

10.  Developing a marker of exposure to xenoestrogen mixtures in human serum.

Authors:  A M Soto; M F Fernandez; M F Luizzi; A S Oles Karasko; C Sonnenschein
Journal:  Environ Health Perspect       Date:  1997-04       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.